Author's reply re: Pravastatin to ameliorate early onset pre-eclampsia: promising but not there yet.

08:00 EDT 10th March 2020 | BioPortfolio

Summary of "Author's reply re: Pravastatin to ameliorate early onset pre-eclampsia: promising but not there yet."

No Summary Available


Journal Details

This article was published in the following journal.

Name: BJOG : an international journal of obstetrics and gynaecology
ISSN: 1471-0528


DeepDyve research library

PubMed Articles [15306 Associated PubMed Articles listed on BioPortfolio]

Pravastatin to Ameliorate Early Onset Preeclampsia: Promising but not there yet.

In this issue, Ahmed at al. (BJOG xxxx) reported the results of the Statins to Ameliorate early onset Preeclampsia (StAmP) trial that was conducted in the UK between 2011-2014, and randomized women wi...

Pravastatin as the statin of choice for reducing pre-eclampsia-associated endothelial dysfunction.

There is avid interest in pravastatin as a therapeutic intervention for pre-eclampsia, however little is known on statin action on endothelial dysfunction. This study aimed to evaluate the ability of ...

Serum Levels of Complement Factors C1q, Bb, and H in Normal Pregnancy and Severe Pre-Eclampsia.

BACKGROUND This study aimed to determine the diagnostic role of serum levels of complement C1q, Bb, and H in nonpregnant women, women with normal pregnancy, and women with severe pre-eclampsia. MATERI...

Pravastatin for early-onset preeclampsia: a randomized, blinded, placebo-controlled trial.

Women with preeclampsia have elevated circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve pregnancy outcome in animals with a p...

A more accurate prediction to rule in and rule out pre-eclampsia using the sFlt-1/PlGF ratio and NT-proBNP as biomarkers.

Background The management of potential pre-eclamptic patients using the soluble FMS-like tyrosine kinase 1 (sFlt-1)/ placental growth factor (PlGF) ratio is characterised by frequent false-positive re...

Clinical Trials [6910 Associated Clinical Trials listed on BioPortfolio]

Use of Sildenafil Citrate in Management of Mild Pre-eclampsia

- Mild pre-eclampsia represents 75% of cases with pre-eclampsia, possible progression to severe pre-eclampsia makes mild pre-eclampsia a serious problem that requires attention. -...

Podocyturia as Predictive Factor for Pre-eclampsia

Pre-eclampsia is an hypertensive disorder appearing during pregnancy, inducing serious maternal, fetal and neonatal mortality and morbidity. Podocyn could be identified in the urine, befor...

Pre-eclampsia/Eclampsia in Italy Over the Years 2010-2016

Pre-eclampsia is a heterogeneous multisystem disorder that complicates 2-8% of pregnancies and remains a leading cause of maternal and perinatal mortality and morbidity. Pre-eclampsia is ...

Statin Therapy in Patients With Early Stage ADPKD

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has b...

Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes

An increased risk of incident diabetes with statin therapy have been reported in several studies. However, it is not recommended to limit the use of statin for this reason since the absolu...

Medical and Biotech [MESH] Definitions

Onset of HYPERREFLEXIA; SEIZURES; or COMA in a previously diagnosed pre-eclamptic patient (PRE-ECLAMPSIA).

A syndrome characterized by multiple system abnormalities including DWARFISM; PHOTOSENSITIVITY DISORDERS; PREMATURE AGING; and HEARING LOSS. It is caused by mutations of a number of autosomal recessive genes encoding proteins that involve transcriptional-coupled DNA REPAIR processes. Cockayne syndrome is classified by the severity and age of onset. Type I (classical; CSA) is early childhood onset in the second year of life; type II (congenital; CSB) is early onset at birth with severe symptoms; type III (xeroderma pigmentosum; XP) is late childhood onset with mild symptoms.

A complication of PREGNANCY, characterized by a complex of symptoms including maternal HYPERTENSION and PROTEINURIA with or without pathological EDEMA. Symptoms may range between mild and severe. Pre-eclampsia usually occurs after the 20th week of gestation, but may develop before this time in the presence of trophoblastic disease.

A small colorless crystal used as an anticonvulsant, a cathartic, and an electrolyte replenisher in the treatment of pre-eclampsia and eclampsia. It causes direct inhibition of action potentials in myometrial muscle cells. Excitation and contraction are uncoupled, which decreases the frequency and force of contractions. (From AMA Drug Evaluations Annual, 1992, p1083)

Work consisting of an acknowledgment of an error, issued by a publisher, editor, or author. It customarily cites the source where the error occurred, giving complete bibliographic data for retrieval. In the case of books and monographs, author, title, imprint, paging, and other helpful references will be given; in the case of journal articles, the author, title, paging, and journal reference will be shown. An erratum notice is variously cited as Errata or Corrigenda.

Quick Search

DeepDyve research library

Relevant Topic

Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...

Searches Linking to this Article